Osiris contracted for stem-cell radiation therapy

The Department of Defense is betting $224 million that Columbia-based Osiris Therapeutics? patented stem cells can reduce gastrointestinal damage caused by exposure to a radiological weapon.

The contract will help Osiris develop and stockpile its adult stem cell therapy, Prochymal, to reduce damage from radiation exposure from so-called dirty bombs or other weapons.